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Background: The spectrum of RB1gene mutations in Retinoblastoma (RB) patients and the necessity of multiple
traditional methods for complete variant analysis make the molecular diagnosis a cumbersome, labor-intensive and
time-consuming process. Here, we have used targeted next generation sequencing (NGS) approach with in-house
analysis pipeline to explore its potential for the molecular diagnosis of RB.
Methods: Thirty-three patients with RB and their family members were selected randomly. DNA from patient blood
and/or tumor was used for RB1 gene targeted sequencing. The raw reads were obtained from Illumina Miseq. An
in-house bioinformatics pipeline was developed to detect both single nucleotide variants (SNVs) and small insertions/
deletions (InDels) and to distinguish between somatic and germline mutations. In addition, ExomeCNV and Cn. MOPS
were used to detect copy number variations (CNVs). The pathogenic variants were identified with stringent criteria, and
were further confirmed by conventional methods and cosegregation in families.
Results: Using our approach, an array of pathogenic variants including SNVs, InDels and CNVs were detected in 85% of
patients. Among the variants detected, 63% were germline and 37% were somatic. Interestingly, nine novel pathogenic
variants (33%) were also detected in our study.
Conclusions: We demonstrated for the first time that targeted NGS is an efficient approach for the identification of
wide spectrum of pathogenic variants in RB patients. This study is helpful for the molecular diagnosis of RB in a
comprehensive and time-efficient manner.
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Retinoblastoma (RB, OMIM#180200), the most common
pediatric eye tumor in the retina is initiated by inactiva-
ting biallelic variants of RB1 gene [1]. Retinoblastoma
occurs in hereditary and non-hereditary forms, with
most bilateral and some unilateral RB cases being here-
ditary. The non-heritable form predominantly leads to
unilateral tumors where in both variants have occurred
in somatic cells and are not transmitted [2]. It is essen-
tial to identify and distinguish the germline and somatic* Correspondence: bharanid@gmail.com; vanniarajan@aravind.org
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unless otherwise stated.variations in RB1 for predicting the accurate risk of RB
in future siblings and offsprings. The retinoblastoma
susceptibility gene, RB1 (Genbank accession number
L11910.1; NCBI RefSeq NM_000321.2) is located on
chromosome 13q14.2 and is composed of 27 exons distri-
buted along 183 kb of genomic sequence. A wide spectrum
of heterogeneous RB1 gene variants that includes – single
nucleotide variations (SNVs), small insertions/deletions
(InDels) and structural variations (SVs) had been re-
ported in RB patients [3]. Some of the variants such as
nonsense and frameshift are associated with bilateral
RB, while other types have unilateral RB or milder
phenotypic expression [4].
Predictive genetic testing of RB can help to save the vi-
sion and avoid unnecessary (and invasive) eye examinationsral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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manner. Currently, the routine procedure for genetic test-
ing of RB1 involves multiple methods of mutation detection
in the coding regions and intron-exon boundaries using
Sanger sequencing, and deletion/duplication analysis by
genotyping methods such as multiplex ligation-dependent
probe amplification (MLPA), quantitative multiplex PCR
(QMPCR) [5]. The major limitations of Sanger sequencing
are the extended time taken for screening all 27 exons indi-
vidually and limited data (2X) generated from the sequen-
cing runs. Thus, identifying the spectrum of heterogeneous
variants in RB1 gene makes the molecular diagnosis of RB
challenging and time-consuming.
Accurate identification of RB1 pathogenic variants in a
reduced time is very important for diagnosis, confir-
mation, genetic counseling, risk assessment, and carrier
screening of RB patients and their family members. Next
Generation sequencing (NGS) has been found to be a
time-efficient and accurate approach for the molecular
diagnosis of simple to complex diseases including cancer
[6-8]. Due to this improved efficiency, NGS has been
widely used as diagnostic tool for retinal dystrophies
[9-12]. In the present study, we have used targeted next
generation sequencing approach with in-house bioinfor-
matics pipeline for the molecular diagnosis of RB for the
first time.
Methods
Clinical diagnosis and patient samples
A total of 21 families with bilateral RB and 12 families
with unilateral RB were selected for this study (Table 1).
The clinical diagnosis of RB was made by thorough clini-
cal examination and radiological investigations (CT/MRI
and USG B scan) along with Retcam imaging in Aravind
Eye Hospital Madurai, India. Retinal examination was per-
formed in family members to detect small scars/pigmentary
changes, which are suggestive of regressed RB. The blood
samples were collected from patients and family members.
In addition, fresh tumor samples were collected from
enucleated patient eyes. The present study was approved
by the Institutional Ethics Committee of Aravind Medi-
cal Research Foundation, Madurai, India (Registration
Number: ECR/182/Arvind/Inst/TN/2013). All the pa-
tient samples were collected after getting the informed
consent from the families.
DNA isolation
Genomic DNA was isolated from blood samples (2 ml
for patients and 5 ml for parents) by salting out method
[13] and tumor by QIAamp® DNA Mini Kit (Qiagen,
Germantown, MD) following the manufacturer’s protocol.
The quality and quantity of the DNA was checked by
Nanodrop 1000 spectrophotometer (Thermo Scientific,
Waltham, USA).Library preparation and targeted next generation
sequencing
Targeted NGS was performed in total of 33 patients. Of
those, 12 were tumor and 21 were blood samples. In
three patients, tumor/blood matched pairs were in-
cluded. In two families, the affected family members
along with the patient were also analysed (Table 1). A
Primer library was custom-designed to amplify 27 exons,
exon/intron boundaries and promoter region of RB1
gene using the Illumina Truseq custom Amplicon and
Agilent SureSelect in-solution hybridization capture kits
by the service provider (Scigenom, Kochi, India). Briefly,
2 μg of each genomic DNA was sheared into 100-500 bp
fragments. Regions of interest were enriched using the
above methods and libraries were prepared. The high
sensitivity DNA chips were used in Agilent Bioanalyzer,
to validate the enrichment process. Quantitative PCR
was used to measure the quantity of the library before
sequencing. Captured libraries were sequenced in a mul-
tiplexed fashion on Miseq with paired end run to obtain
2×150 bp reads with at least 100X depth of coverage.
The coding region with <20X depth of coverage were
covered by Sanger sequencing.
SNV and InDel detection
Obtained raw sequence reads from Miseq were analysed
using bioinformatics pipeline as shown in Figure 1. Data
was quality filtered using fastQC tool [14]. The filtered
reads were mapped to Hg19 reference sequence using
Burrow-Wheeler Aligner (BWA version 0.7.5a-r405)
[15]. Resulting BAM files were locally realigned using
GenomeAnalysisTK-3.1-1 (GATK) Indel-realigner [16]
tool to minimize the mismatches across the reads. GATK
haplotype caller was performed to retrieve germline single
nucleotide variants (SNVs) and small insertions/deletions
(InDels) with phred score 20 and minimum depth 5 from
all the samples. MuTect-1.1.4 [17] and GATK Indelocator
tools were used to identify somatic SNVs and InDels from
the tumor samples with blood matched control respec-
tively. Wherever matched blood sample is not available,
the blood sample with similar coverage was used. All the
SNVs and InDels were subjected to identify rare and
potential variants. The rare variants were identified using
ANNOVAR [18] by filtering common variants with
alternative allelic frequency higher than 1% based on 1000
Genomes project (http://www.1000genomes.org/data),
dbSNP135 (http://www.ncbi.nlm.nih.gov//SNP) and
ESP (http://evs.gs.washington.edu/EVS). Of those, non-
synonymous/synonymous SNVs, coding InDels, and intronic
variants that were less than 10 bp beyond the canonical
splice site junction were selected. The potential variants
were identified using ClinVar (http://www.ncbi.nlm.nih.
gov/clinvar/), COSMIC (http://cancer.sanger.ac.uk/cosmic)
and In-house (reported pathogenic variants) databases.
Table 1 Clinical & family history of RB patients and samples selected for NGS
Patient no Age (months)/Sex Laterality Family history Samples analysed by NGS
RB1 4/F Bilateral Father with regressed RB Patient’s blood
RB2 1/F Bilateral Father with regressed RB Patient’s blood
RB3 33/F Bilateral Nil Patient’s blood
RB4 4/M Bilateral Mother and sibling affected with RB Patient’s blood
RB5 0/F Bilateral Nil Patient’s blood
RB6 31/F Bilateral Three siblings affected with RB Patient’s blood
RB7 39/F Bilateral Father affected with RB Patient’s and Father’s blood
RB8 44/M Unilateral Nil Patient’s blood and tumor
RB9 7/F Unilateral Nil Patient’s tumor
RB10 0/M Unilateral Nil Patient’s tumor
RB11 5/F Unilateral One sibling affected with RB Patient’s and Sibling’s blood
RB12 14/M Unilateral Nil Patient’s blood and tumor
RB13 12/M Bilateral Nil Patient’s blood
RB14 44/F Bilateral Father and sibling affected with RB Patient’s blood
RB15 11/M Bilateral Father affected with RB Patient’s blood
RB16 0/M Bilateral Nil Patient’s blood
RB17 0/M Bilateral Father and sibling affected with RB Patient’s blood
RB18 26/F Bilateral Nil Patient’s blood
RB19 36/F Bilateral Nil Patient’s blood
RB20 31/M Bilateral Nil Patient’s blood
RB21 12/M Unilateral Nil Patient’s tumor
RB22 18/F Unilateral Nil Patient’s tumor
RB23 19/M Bilateral Father and sibling affected with RB Patient’s blood
RB24 26/F Bilateral Nil Patient’s blood
RB25 8/F Bilateral Nil Patient’s blood and tumor
RB26 12/F Bilateral Nil Patient’s blood
RB27 66/F Bilateral Nil Patient’s blood
RB28 58/F Unilateral Nil Patient’s tumor
RB29 28/M Unilateral Nil Patient’s tumor
RB30 18/M Unilateral Nil Patient’s tumor
RB31 88/M Unilateral Nil Patient’s tumor
RB32 27/M Unilateral Nil Patient’s tumor
RB33 3/M Bilateral Nil Patient’s blood
The age at which first sign was detected is given in months. Laterality was confirmed by the clinical investigations and imaging (CT Scan/MRI, Ultrasound, Retcam).
Family history was ascertained by three or four generation pedigree. NGS was performed on patient’s tumor wherever available. In three patients (RB8, RB12 and RB25),
both blood and tumor samples were analyzed. In two families, affected members were also included for NGS along with patients (RB7 and RB11).
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automated. Detected variants were further manually
assessed with the help of IGV-2.3.25 viewer to avoid
mapping errors.
Copy number variation (CNV) detection
The locally realigned BAM files were used to detect
CNV. ExomeCNV [19], a statistical tool that uses cover-
age and alternative allele frequencies to estimate CNV,was used to detect somatic CNVs from the tumor/blood
pairs as described above. Whereas, Cn. MOPS [20], a
read count based CNV caller was used to detect the
germline CNVs in the blood samples. More than five
blood samples with similar exon coverage were used to
improve the sensitivity of Cn. MOPS. Log Ratios
(LogR) ≥ ±1 were set for Deletion/Duplication analysis
in both the tools; median LogR score were used for
Cn. MOPS.
Blood and Tumor Samples
Raw Read Preprocessing
Illumina Paired-EndTargeted RB1 Region
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Human Splice Site Finder 
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Figure 1 Analysis pipeline to identify pathogenic variants in tumor
and blood samples from retinoblastoma patients.
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In order to identify pathogenic variants, we used the fol-
lowing criteria. i) known pathogenic variants; ii) if not,
variants that could give rise to premature protein termi-
nation, frameshift, canonical splice site alterations and
large exonic deletions; iii) nonsynonymous SNVs if Sift
[21], Polyphen2 [22] and MutationTaster [23] all sug-
gested pathogenic, and iv) splice variants selected from
both Human splice site finder [24] and MaxEntScan [25].
Confirmation of variants by Sanger sequencing and MLPA
All the pathogenic variants were confirmed by Sanger
sequencing, MLPA and cosegregation analysis in blood
and tumor samples of patients, and blood samples of
family members. PCR amplification of the corresponding
exon around the variant site of the RB1 gene was per-
formed. Each 25 ul reaction contained 20 ng of genomic
DNA, 10XPCR Buffer, 100 mM dNTPS, 10uM of each
forward and reverse primer and 1U of Taq DNA polymer-
ase (Sigma Aldrich, Missouri, USA) with cycling condi-
tions and PCR primers described previously [26]. Cycle
sequencing was performed using the BigDye Terminator
kit version 3.1 and purified products were analyzed on a
3130 Genetic Analyzer (Life Technologies, USA). MLPA
was performed with SALSA MLPA kit P047-RB1 kit(MRC-Holland, Amsterdam, The Netherlands) according
to manufacturer’s instructions. Fragment analysis was per-
formed with Gene Mapper software (Life Technologies,
USA) and data was analyzed using Coffalyser software
(MRC, Holland) where DNA copy number ratios of tumor
samples were computed using the matched blood sample.
For genes targeted by multiple probes, copy number ratios
were averaged. A threshold ratio of >1.3 denotes duplica-
tion and a ratio of <0.7 denotes deletion. Size fractionation
was carried out by agarose gel electrophoresis to confirm
deletions ranging from 10 to 30 bp.
Targeted sequencing using Ion-Torrent Personal Genome
machine (PGM)
In order to compare the data obtained from Miseq, eight
patients were selected randomly for the cross platform
comparison. Of those, six were blood from patients RB2,
RB4, RB7, RB13, RB24, RB25 and two were tumor/blood
matched pairs of samples from RB8 and RB12. Sequen-
cing was performed with Ion-Torrent PGM at University
of Pennsylvania, Philadelphia using the protocol as de-
scribed [27]. Briefly, multiplex PCR was performed to
generate the PCR fragments of all 27 exons of RB1 using
Qiagen multiplex PCR kit. Ion Xpress Plus gDNA Frag-
ment Library Preparation kit was used for shearing,
adapter ligation and nick repair. Emulsion PCR was per-
formed with One Touch2 system and enrichment with
One Touch ES using 200 bp chemistry. Purification was
performed at each step with Ampure beads (Agencourt)
and quality was checked using the Bioanalyzer. The final
enriched libraries were sequenced on Ion PGM with 318
chip. The sequence reads were aligned against the
human RB1 genomic sequence [GenBank Accession
L11910.1] and variant calling were made using Ion
Torrent Suite (Life Technologies) as described [27]. The
reads were automatically barcode-sorted followed by re-
moval of the reads with low quality. The BAM and BAI
files of Ion PGM runs were checked visually on IGV-




Thirty three patients with RB as shown in Table 1 from un-
related Indian families were selected for this study of tar-
geted RB1 sequencing. Illumina Truseq Custom Amplicon
was used for target amplification in 23 samples (RB1-RB23)
and Agilent SureSelect enrichment method was used for
other 10 samples (RB24-RB33). Paired end sequencing
in Miseq covered nearly 3000 bases of RB1 encompas-
sing 27 exons along with their flanking intron and pro-
moter regions. The mean depth of coverage was found
to be ~ 200X with Truseq and ~150X with SureSelect.
The average sequencing coverage of the targeted regions
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as exons 14 and 20 were not covered sufficiently (<20X)
in Truseq. The missed regions were covered by Sanger se-
quencing. Therefore, complete coverage of all the target
bases was ensured to provide high quality bases for sensi-
tive and efficient variant detection. An automatic in-house
variant calling pipeline was developed using freely avail-
able tools to detect germline SNVs and InDels for all the
samples, wherein the tumor samples were checked for
somatic SNVs and InDels. With stringent criteria, patho-
genic SNVs and InDels were identified and patients with
no pathogenic variants were further analysed for copy
number variations (CNVs). ExomeCNV and Cn. MOPS
were used to detect somatic and germline CNVs in tumor
and blood samples respectively. All the pathogenic va-
riants were further confirmed by conventional methods
and cosegregation. Somatic events were re-confirmed by
their absence in same patient blood sample.
Identification of germline SNVs and InDels in RB patients
Blood samples of 21 bilateral (familial and sporadic) pa-
tients and one familial unilateral patient (Table 1), were
analyzed to detect SNVs and InDels. Pathogenic variants
were identified in 15 patients, of which eight were novel
and seven were previously reported (Table 2). Surpri-
singly, all the reported pathogenic variants were found
to be nonsense variants, resulting in premature protein
termination. Five of them were shown to be de novo as
only the patient had the mutation and not the family
members, and remaining two were inherited from one
of their parents (Table 1 and 2).Table 2 RB1 variants identified by targeted NGS in blood sam
Patient no cDNA change Amino acid change Func
RB1 c.-212_-195del Prom
RB2 c.1399C > T p.R467X Prem
RB4 c.265-9 T > A Altere
RB11 c.46_74del p.A16AfsX14 Fram
RB13 c.751C > T p.R251X Prem
RB14 c.2520 + 4 A > G Altere
RB15 c.2115_2118del p.M705IfsX8 Fram
RB16 c.1363C > T p.R455X Prem
RB17 c.1960 + 2 T > A Altere
RB18 c.38_66del p.A13AfsX17 Fram
RB19 c.1399 C > T p.R467X Prem
RB24 c.1961_1963del p.654_655del Altere
RB25 c.1072C > T p.R358X Prem
RB26 c.521 T > A p.L174X Prem
RB27 c.160G > T p.E54X Prem
Novel variants are marked in bold. Cosegregation of the variants was confirmed byThe novel pathogenic variants either caused aberrant
splicing or frameshift due to deletions. Four variants
identified in patients RB4, RB14, RB17 and RB24 were
found to affect splicing based on the HSF and MaxEntScan
tools (Table 2). Patient RB4 was found to have a heterozy-
gous c.265-9 T >A intronic variant at the upstream of ac-
ceptor splice site, which was predicted to activate a cryptic
splice site (9 bases prior to exon 3) that may result in
frameshift. In case of patient RB14 and RB17, heterozy-
gous intronic variants near canonical splice sites might re-
sult in altered splicing. Three patients RB4, RB14 and
RB17 had affected members in the family showing the
same variant as that of the patient. As an example, cose-
gregation of variant in the family of Patient RB4 was
shown in Figure 2A. Interestingly, a de novo heterozygous
in-frame deletion of three bases identified at the start site
of exon 20 in patient RB24 was considered to be deleteri-
ous, which might result in splicing defect (Figure 2B).
A heterozygous deletion of 17 bases at the upstream
of ORF in the promoter region was detected in patient
RB1, which was confirmed by agarose gel electropho-
resis. The deletion was also detected in father, who was
diagnosed as regressed RB (Figure 3A). In addition,
frameshift deletions were detected in three patients.
One patient RB15 had deletion of four bases which was
also detected in his father. A deletion of 29 bases in
exon 1 was identified in patient RB18. In family of
patient RB11, a deletion of 29 bases at another locus
of exon 1 was observed in all members except father
(Figure 3B), where one sibling was affected with
RB (Table 1).ples of RB patients
tional consequence Cosegregation in family
oter Deletion Heterozygous Father
ature Protein Termination Heterozygous Father
d Splicing Heterozygous Mother and Sibling
eshift Heterozygous Mother and three Siblings
ature Protein Termination De novo
d Splicing Heterozygous Father
eshift Heterozygous Father
ature Protein Termination De novo
d Splicing Heterozygous Father and Sibling
eshift De novo
ature Protein Termination Heterozygous Mother
d Splicing De novo
ature Protein Termination De novo
ature Protein Termination De novo
ature Protein Termination De novo




























Figure 2 Confirmation of novel pathogenic splice variants. (A) Cosegregation of variants in the family was confirmed by Sanger sequencing
of blood samples of Patient RB4, his mother and sibling, who had heterozygous c.265-9 T > A variant that created a new splice site acceptor.
(B) Patient RB24 had a de novo heterozygous in-frame deletion of three bases identified at the start site of exon 20. Red arrows denote the variant.
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samples
Somatic variants were detected in tumor samples of 7
out of 11 patients with sporadic unilateral RB (Table 1

















Figure 3 Agarose gel electrophoresis for the confirmation of small deletion
samples of patient RB1 and his father. (B) 29 bp deletion in Exon 1 was ob
size of actual and deleted product is indicated by straight and dotted arrowpatients (RB10, RB12, RB22 and RB29) and two hetero-
zygous variants were identified in other 3 patients (RB8,
RB9 and RB31). Of the homozygous variants, three were
nonsense variants in patient RB10, RB12 and RB29,































s. (A) 17 bp deletion in the Promoter region was observed in blood
served in blood samples of patient RB11, her mother and siblings. The
s respectively in both gels.
Table 3 RB1 variants identified by targeted NGS in tumor samples of RB patient
Patient no cDNA change Amino acid change Functional consequence
RB9 c.380G > A/c.1363C > T p.S127N/p.R455X Missense-Altered splicing/Premature Protein Termination
RB10 c.763C > T* p.R255X* Premature Protein Termination
RB12 c. 1072C > T* p.R358X* Premature Protein Termination
RB22 c.1732_1733delGinsTT* p.D578LfsX6 * Frameshift
RB29 c.1654C > T* p.R552X* Premature Protein Termination
RB31 c.409 G > T/c.751 C > T p.E137X/p.R251X Premature Protein Termination Premature Protein Termination
Novel variant is marked in bold. In patients RB10, RB12, RB22 and RB29, homozygous variants (marked with *) were identified. All the variants given in the table
were somatic variants as they were detected only in patient’s tumor but not in blood samples of patient and family members.
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riant were identified in both Patients RB8 and RB9, and
two nonsense variants were identified in patient RB31.
In addition, a somatic loss of heterozygosity (LOH) was
detected in tumor sample of Patient RB25, where the
germline heterozygous nonsense variant (c.1072C > T)
was converted to homozygous (Table 2). All the somatic
variants and zygosity were confirmed by Sanger sequen-
cing in patient tumor and blood samples. Our results are
consistent with the Knudson’s two hit hypothesis [28] in
all the patients as we have identified either homozygous
or two heterozygous variants.
Detection of copy number variations (CNVs)
Eleven samples with no pathogenic SNVs and InDels were
subjected to the analysis of CNVs. For blood samples, we
utilized the tool Cn. MOPS, which detected five hetero-
zygous germline CNVs in four samples. Deletion found in
each patient sample RB3, RB5, RB6, RB7 was confirmed
by MLPA (Table 4). Of those, deletion of exon 10-12 in
patient RB7 cosegregated with phenotype (Figure 4A).
Another deletion (exon 22) in patient RB6 detected by Cn.
MOPS, was not found by MLPA. Somatic deletions in-
cluding a homozygous deletion of Exon10 in patient RB21
and a heterozygous deletion of Exons 7-27 in patient
RB32 (Figure 4B) were observed using ExomeCNV, whichTable 4 Copy number variations (CNVs) identified in tumor/b
Patient no CNV logR Metho
RB3 Deletion of whole RB1 -1.0 Cn. MO
RB5 Deletion of exons 4-6 -1.0 Cn. MO
RB6 Deletion of exon 22 -1.0 Cn. MO
RB6 Deletion of exons 24-25 -5.5 Cn. MO
RB7 Deletion of exons 10-12 -1.2 Cn. MO
RB21 Deletion of exon 10 -5.4 ExomeC
RB32 Deletion of exons 7-27 -1.1 ExomeC
Two programs, Cn. MOPS and ExomeCNV were used to identify germline and soma
confirmed and cosegregation was observed by MLPA. The exon 22 deletion identifi
deletion identified in patient RB21, all other CNVs were heterozygous.were further confirmed by MLPA (Table 4). Overall, 80%
and 100% sensitivity were observed in detecting germline
and somatic CNVs respectively.
Cross platform comparison of Illumina Miseq and
ion-torrent PGM results
The five pathogenic variants detected in patients RB2,
RB4, RB13, RB24 and RB25 (Table 2) were concordant
with Ion PGM results. Both platforms detected somatic
variants in tumor samples (Table 3) and their absence in
blood samples of same patients (RB8 and RB12). However,
deletion found in patient RB7 (Table 4) was not detected
by Ion Torrent Suite. Further, analysis by Cn. Mops could
not be carried out because of small sample size.
Unsolved cases
No pathogenic variants were detected in five patients
(RB20, RB23, RB28, RB30 and RB33) with our approach.
Rare variants not following our criteria for pathogenicity
and deep intronic variant were excluded. For example,
in two unsolved cases (RB20 and RB23) one missense
variant (Exon19, c.A1846G, p.K616E) was detected. Al-
though it was reported in Human Gene Mutation Data-
base (HGMD) [29], it was not predicted as pathogenic
with SIFT, Polyphen2 and MutationTaster tools. It was also
observed in more than 12 patients with low coverage andlood samples of Retinoblastoma patients
d used Cosegregation in family MLPA confirmation
PS De novo Yes
PS De novo Yes
PS - No
PS Heterozygous Father Yes
PS Heterozygous Father Yes
NV - Yes
NV - Yes
tic CNVs from blood and tumor samples respectively. CNVs identified were


























Figure 4 Confirmation of copy number variations (CNVs) by MLPA. (A) Patient RB7 had an affected father and both of them showed deletion of
exons 10-12. (B) Patient RB32 had a somatic deletion of exons 7-27 which was not detected in blood. The deletions were denoted by the red
spots below the deletion cut-off line (red) in the ratio chart.
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one deep intronic variant (exon 3, c.380 + 150 T >A),
reported in COSMIC database (ID = COSM164493) and
detected in patient RB30, RB23 and RB33 was excluded
from the analysis. Moreover it was found to be polymor-
phism in dbSNP and observed in more than 80% of our
patient samples.
Discussion
Retinoblastoma, the most common childhood intra-
ocular tumor has complex genetic basis of cancer deve-
lopment, initiated by biallelic inactivation of RB1 gene
[28]. Genetic testing of RB1 will be beneficial to provide
counselling for families. However, genetic analysis of
heterogeneous spectrum of variants in RB1 gene is no
trivial task [4] and essentially requires comprehensive
approach. Here, we have used NGS approach for the
molecular analysis of Indian patients with RB, based on
RB1 gene target enrichment, multiplexing and bioin-
formatics pipeline. We used in-house pipeline to suc-
cessfully detect both pathogenic germline and somatic
variants in RB patients. With our approach, we were able
to identify heterogeneous spectrum of RB1 gene variants
including SNVs, InDels and CNVs. All the variants
detected were validated using Sanger sequencing, MLPA
and size fractionation methods. Thus, our approach,achieving a diagnostic rate of 85%, proved to be efficient
for the molecular diagnosis of RB. Moreover, the cross
platform comparison with Ion-Torrent PGM results fur-
ther confirmed the efficiency of NGS.
An important consideration about NGS for diagnosis
is identifying the pathogenic variants among the large
number of variants detected. In order to identify patho-
genic variants, we used stringent criteria after several
modifications during the pipeline development. The fil-
tering process has been set to include synonymous and
polymorphic variants as potential variants if they are
present in cancer and disease databases. While those not
present in any databases were classified as rare variants.
By applying stringent criteria, we could detect known
and novel pathogenic variants with no false positives.
For example, a novel intronic variant (c.265-9 T > A) in
patient RB4 (Figure 2A) creates a cryptic splice site and
is most likely a pathogenic variant. We further con-
firmed its pathogenicity by cosegregation with pheno-
type. However, another splice variant (c.1961_1963del)
in patient RB24 (Figure 2B) as predicted as most likely
pathogenic did not co-segregate with phenotype. Ulti-
mately, functional studies are necessary for assigning
pathogenicity to these novel variants.
The limitation of the targeted NGS is the uneven cap-
ture efficiency that reduced the sensitivity of detection
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the library prepared with Illumina-Truseq and also there
were no coverage of exon 14 and few regions of exon 20.
This drawback was overcome with the Agilent Sureselect
method. However, variable depth of coverage was noted
in exons 1 and 27 (10-200X). Hence uniform capture
efficiency with a higher depth of RB1 sequencing will re-
solve the issues.
In addition to the technical limitation of the targeted
NGS, complete RB1 sequencing is needed to detect the
missed variants in the deep intronic and untranslated re-
gions (UTRs) that could possibly reduce the five un-
solved cases. However, there are other factors that can
initiate RB, such as promoter methylation of RB1 gene,
and MYCN gene amplification [30]. In fact, we found
MYCN amplification in tumor sample of a unilateral pa-
tient RB30 (data not shown). Hence, we propose that
NGS panel for RB should include MYCN gene along
with RB1.
Overall, targeted NGS approach is becoming more
feasible and efficient in clinical settings, especially for
cancer and can potentially identify germline and somatic
variants comprehensively. However, we still suggest con-
ventional methods for validation of the variants as we
are in the initial phase of developing NGS methods for
the diagnosis of RB. Further studies are necessary for
the establishment of this approach in terms of cost-
effectiveness.
Conclusions
This is the first such study (to the best of our knowledge)
using multiplexed targeted NGS approach to detect pa-
thogenic variants in the RB1 gene. We reported here that
this approach with bioinformatics pipeline could detect
germline and somatic variants including novel pathogenic
variants. We demonstrated for the first time that this ap-
proach could detect copy number variations (CNVs) in
RB1 gene. This comprehensive approach reduces the time
and number of assays required for the detection of patho-
genic variants by conventional methods. Our approach is
sensitive (0.97) and efficient for RB1 screening.
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